Long-Term Safety and Efficacy of Escitalopram

Cardiovascular Considerations

The European Society of Cardiology and regulatory agencies such as the FDA and EMA have issued warnings about QT interval prolongation with escitalopram, leading to maximum dose restrictions, particularly in patients over 60 years 2
The risk of QT interval prolongation increases in a dose-dependent manner, particularly at doses of 20 mg/day, emphasizing the need for ECG monitoring in patients with cardiac risk factors or those on higher doses 2

The American College of Physicians suggests that escitalopram may be associated with a low risk of suicidality, particularly in younger patients, though no completed suicides were reported in clinical trials, highlighting the importance of monitoring for emergence of suicidal ideation 3
The European Psychiatric Association notes that long-term cognitive impairment is generally not a significant concern with escitalopram, unlike some other psychotropic medications, with concentration and memory issues being uncommon compared to tricyclic antidepressants 2, 4

The American Academy of Family Physicians recommends tapering escitalopram over 10-14 days to limit withdrawal symptoms, which can include lethargy, general malaise, and sensory disturbances, particularly in patients with a history of substance abuse or dependence 1, 4
The Royal College of Psychiatrists suggests that escitalopram has a half-life of 27-33 hours, which may reduce discontinuation symptoms compared to shorter-acting SSRIs, but lightheadedness and dizziness may be more pronounced during discontinuation 1

The National Institute for Health and Care Excellence recommends starting with lower doses (10 mg/day) and gradually titrating to minimize gastrointestinal and CNS side effects, with the option to take medication at bedtime if daytime dizziness is problematic 1
The American Heart Association suggests ensuring adequate hydration and rising slowly from sitting or lying positions to minimize orthostatic effects, particularly in patients with a history of orthostatic hypotension 1